Selective serotonin reuptake inhibitors as a risk factor for dental implant failure: a retrospective clinical study

doi:10.1016/j.bjoms.2022.09.009

Q4 · MedicineImpact Factor · 0.501

AutoresKaren Rodríguez-Pena, Ángel-Orión Salgado-Peralvo, Naresh Kewalramani, Juan-Antonio Suárez-Quintanilla, José-María Suárez-Quintanilla

Por qué importa

Este estudio retrospectivo evalúa la posible asociación entre el consumo de antidepresivos inhibidores selectivos de la recaptación de serotonina (ISRS) y el fracaso de implantes dentales. Se observó una tasa de fracaso significativamente mayor en pacientes tratados con ISRS en comparación con aquellos que no los consumían. Específicamente, el uso de estos fármacos se relacionó con un riesgo de fracaso de implantes 4.53 veces mayor, y un riesgo ajustado 3.70 veces superior en el análisis multivariante. Además, la tasa de supervivencia de los implantes a 90 meses fue inferior en el grupo de pacientes con ISRS. Los resultados sugieren una relación entre la ingesta de ISRS y una menor tasa de éxito de los implantes dentales, un factor a tener en cuenta en la planificación y seguimiento de tratamientos implantológicos.

Abstract original

The trend in recent decades in Europe and the United States points to an exponential increase in the consumption of antidepressant drugs and, in particular, selective serotonin reuptake inhibitors (SSRIs). This retrospective study aimed to investigate whether there is an association between SSRI intake and dental implant (DI) failure or survival and, secondarily, to investigate the influence of other systemic and local factors. This retrospective cohort study was done in accordance with the the STROBE (Strengthening the Reporting of Observational Studies in Epidemiology) guidelines for observational studies. A total of 170 patients received 573 DIs between 2014 and 2020.The reported DI failure rate was 6.11% (n = 35 DIs). Of these 18.31% failed in patients treated with SSRIs while 4.38% failed in patients who were not prescribed SSRIs (p < 0.001). Specifically, use of these drugs was associated with a hazard ratio rate of DI failure that was 4.53 times higher (95% CI: 1.93 to 10.61), and in the multivariate analysis, a 3.70 times higher adjusted risk was found. A lower DI survival rate at 90 months' follow up was also observed in these patients compared with those not taking them (84.30% vs 96%, respectively; p = 0.00014). With the limitations of the present study it can be affirmed that there is a relation between the intake of SSRIs and DI failure, as well as a lower survival rate in these patients.

Leer texto completo ↗DOI · 10.1016/j.bjoms.2022.09.009

Autores Doctor&Cols

Cómo citar

Rodríguez-Pena K, Salgado-Peralvo Á, Kewalramani N, Suárez-Quintanilla J, Suárez-Quintanilla J. Selective serotonin reuptake inhibitors as a risk factor for dental implant failure: a retrospective clinical study. British Journal of Oral and Maxillofacial Surgery. 2022. doi:10.1016/j.bjoms.2022.09.009